Syncona Portfolio Ltd Buys Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL

Syncona Portfolio Ltd bought a new stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 16,640,720 shares of the company’s stock, valued at approximately $26,625,152,000. Autolus Therapeutics comprises about 100.0% of Syncona Portfolio Ltd’s holdings, making the stock its biggest position. Syncona Portfolio Ltd owned 6.25% of Autolus Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of AUTL. GAMMA Investing LLC boosted its holdings in Autolus Therapeutics by 115.6% during the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after acquiring an additional 8,309 shares during the period. Independent Advisor Alliance purchased a new stake in Autolus Therapeutics in the fourth quarter worth $28,000. Marex Group plc purchased a new stake in Autolus Therapeutics in the second quarter worth $28,000. Waverly Advisors LLC bought a new stake in shares of Autolus Therapeutics during the first quarter worth $37,000. Finally, SmartHarvest Portfolios LLC purchased a new stake in shares of Autolus Therapeutics during the fourth quarter valued at $43,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on AUTL shares. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Finally, Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $2.15 on Monday. The firm has a 50 day moving average of $1.64 and a 200 day moving average of $1.57. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $572.24 million, a price-to-earnings ratio of -2.03 and a beta of 2.07. Autolus Therapeutics PLC Sponsored ADR has a 52 week low of $1.17 and a 52 week high of $2.43.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. The business had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. On average, sell-side analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.8 earnings per share for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.